{{Rsnum
|rsid=1902023
|Gene=UGT2B15
|Chromosome=4
|position=68670366
|Orientation=minus
|GMAF=0.4371
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=UGT2B15
}}{{PMID Auto
|PMID=19572376
|Title=Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism
}}

{{omim
|desc=URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B15; UGT2B15
|id=600069
|rsnum=1902023
}}

{{omim
|desc=URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B17; UGT2B17
|id=601903
|rsnum=1902023
}}

{{omim
|desc=URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 2 FAMILY, MEMBER B28; UGT2B28
|id=606497
|rsnum=1902023
}}

{{PharmGKB
|RSID=rs1902023
|Name_s=UGT2B15:Y85D; UGT2B15:D85Y; UGT2B15*2
|Gene_s=-
|Feature=
|Evidence=PubMed ID:15961980
|Annotation=N=24 Korean; PK: UGT2B15*2/*2 group vs UGT215*1/*1 showed 0.58 lower systemic clearance of lorazepam; p less than 0.001
|Drugs=lorazepam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110588
}}

{{PharmGKB
|RSID=rs1902023
|Name_s=D85Y
|Gene_s=-
|Feature=
|Evidence=PubMed ID:15044558
|Annotation=Study in human liver microsomes from 54 patients, primarily of Caucasian (n=48) descent: D85Y genotype showed a significant effect (p = 0.012) on S-oxazepam glucuronidation with lower median activities in 85Y/Y livers (49 pmol/min/mg protein) compared with 85D/D livers (131 pmol/min/mg), whereas 85D/Y livers were intermediate in activity (65 pmol/min/mg).
|Drugs=oxazepam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165108042
}}

{{PharmGKB
|RSID=rs1902023
|Name_s=291G/T; D85Y
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19916996
|Annotation=Risk or phenotype-associated allele(s): T/T . Phenotype: Median oxazepam apparent oral clearance was significantly lower in 85YY subjects (1.62 ml min(-1) kg(-1)) compared with 85DD subjects (3.35 ml min(-1) kg(-1); P= 0.003, Student-Newman-Keuls test), whereas 85DY subjects were intermediate (2.34 ml min(-1) kg(-1); P= 0.018 vs. 85DD, P= 0.034 vs. 85YY). Regression analysis indicated that UGT2B15 D85Y genotype accounted for 34% of interindividual variability. Study size: 30. Study population/ethnicity: healthy male subjects.
|Drugs=oxazepam
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110493
}}{{PMID Auto
|PMID=19572200
|Title=Prediction of deleterious non-synonymous single-nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase genes.
|OA=1
}}

{{PMID Auto
|PMID=19847790
|Title=Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15.
|OA=1
}}

{{PMID Auto
|PMID=21614655
|Title=UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women.
}}{{GET Evidence
|gene=UGT2B15
|aa_change=Asp85Tyr
|aa_change_short=D85Y
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1902023
|overall_frequency_n=8
|overall_frequency_d=102
|overall_frequency=0.0784314
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=6
|n_articles=0
|n_articles_annotated=0
|nblosum100=7
|autoscore=0
|webscore=N
}}
{{PMID Auto
|PMID=24267955
|Title=Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study
|OA=1
}}

{{on chip | 23andMe v4}}